Prognostic Impact of 18-F-Florbetaben Amyloid PET Imaging in Patients with Isolated Increases in Cerebrospinal Fluid Phospho-Tau Biomarkers: A Longitudinal Study

Article type: Short Communication

Authors: Jardel, Amory^a | Hopes, Lucie^a | Malaplate, Catherine^b | Roch, Véronique^c | Manca, Chloé^c | Jonveaux, Thérèse Rivasseau^a | Verger, Antoine^{c; d; *}

Affiliations: [a] Department of Neurology and Geriatrics, CHRU-Nancy, Lorraine University, Nancy, France | [b] Molecular Biology and Nutrition, CRB, Department of Biochemistry, CHRU-Nancy, Lorraine University, Nancy, France | [c] Department of Nuclear Medicine and Nancyclotep Imaging Platform, CHRU-Nancy, Lorraine University, Nancy, France | [d] IADI, INSERM, Lorraine University, Nancy, France

Correspondence: [*] Correspondence to: Antoine Verger, MD, PhD, Université de Lorraine, Department of Nuclear Medicine and Nancyclotep Imaging Platform, Rue du Morvan, 54500 Vandoeuvre-les-Nancy, France. Tel.: +33383155567; Fax:+ 33383153839; E-mail: [email protected].

Abstract: This longitudinal study evaluates the prognostic impact of amyloid PET in patients suspected of Alzheimer’s disease and presenting with isolated cerebrospinal fluid (CSF) increases in P-Tau proteins (NCT02556502). The rate of conversion, based on the DSM-5 criteria and all collected data (average follow-up of 39.2±13.2 months), was determined by a panel of experts blinded to the PET results and was 75%(6/8) for positive and 35%(6/17) for negative baseline amyloid PET. In this population with isolated CSF increases in P-Tau, a positive baseline amyloid PET was associated with greater than twice the proportion of dementia conversions within the following three years.

Keywords: Alzheimer’s disease, amyloid PET, cerebrospinal fluid, conversion, longitudinal

DOI: 10.3233/JAD-201435

Journal: Journal of Alzheimer's Disease, vol. 80, no. 4, pp. 1389-1394, 2021